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ABSTRACT
This study evaluated the ability of the Murex HIV
Ag ⁄Ab Combination assay to detect human
immunodeﬁciency virus (HIV) antibodies in
12 617 dried blood spots (DBSs) on ﬁlter paper.
The assay had an overall sensitivity of 99.6% and
a speciﬁcity of 99.9%. In view of its ability to
detect p24 antigen and both HIV-1 and HIV-2
antibodies in samples collected in the form of
DBSs, the Murex Ag ⁄Ab Combination assay is
suitable for use as a standard screening assay for
seroprevalence studies, as well as for routine
diagnostic use in clinical laboratories.
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Early knowledge of human immunodeﬁciency
virus (HIV) serostatus is an important element in
HIV prevention and treatment. Laboratory meth-
ods for diagnosing HIV infection can be classiﬁed
into those that detect HIV antibody, p24 antigen
or viral nucleic acid [1]. Ideally, to maximise the
detection of HIV-infected individuals, viral anti-
gen and ⁄ or viral nucleic acid tests should be used
during the early viraemic window period before
antibodies are detectable. However, viral nucleic
acid tests are not available in many routine diag-
nostic laboratories, as they require an expensive
infrastructure and a high degree of technical
expertise, while serological tests were initially
time-consuming and expensive, particularly as it
was necessary to perform separate tests for HIV
antibody and p24 antigen for a particular indi-
vidual
During the late 1990s, combination assays in an
ELISA format with the ability to detect HIV
antibody and p24 antigen simultaneously were
developed, thereby eliminating the need to per-
form separate assays and decreasing the asso-
ciated costs signiﬁcantly [2–9]. Several studies
have demonstrated that these antigen ⁄ antibody
(Ag ⁄Ab) combination assays are more sensitive
than antibody assays alone [2–5,9,10], thereby
reducing the diagnostic window. Although sev-
eral preliminary reports have described the use of
the Murex HIV 1.2.0 kit (a third-generation kit;
Murex Biotech, Dartford, UK) in conjunction with
dried blood spot (DBS) samples (http://
www.hivtestingconference.org/PA22.htm), no
such data are available for the Murex HIV Ag ⁄Ab
Combination assay (Murex Biotech). The present
study evaluated the feasibility of using the Murex
Ag ⁄Ab Combination assay to detect HIV-1 and
HIV-2 antibodies, as well as p24 antigen, in
specimens collected in the form of DBSs.
Following approval from the Institutional
Ethics Committees, six DBSs were obtained
from each of 12 617 individuals in the Guntur
district of Andhra Pradesh, India, as part of a
population-based study of HIV [11]. DBSs were
stored at room temperature for £1 week in the
ﬁeld study ofﬁce, and then at 2–8C in the
laboratory until required for testing. No loss of
sensitivity in the detection of HIV in DBSs has
been observed in previous studies in which the
DBSs were refrigerated for up to 20 weeks and
36 months before performing ELISA and PCR
assays, respectively [12,13].
Elution was initially standardised using 48
conﬁrmed HIV-reactive DBSs on ﬁlter paper.
The Murex Ag ⁄Ab Combination assay requires
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that ‡100 lL of specimen be added to the ELISA
wells, but each 6-mm piece of a DBS on ﬁlter
paper absorbs 30–40 lL of solution. For these
reasons, a 6-mm piece from each of the 48 HIV-
reactive DBS samples was eluted with 150, 200,
250 and 500 lL of phosphate-buffered saline
(PBS) and incubated overnight at 2–4C, after
which 100 lL of each eluate was used to perform
the Murex HIV Ag ⁄Ab Combination assay. All 48
DBSs were positive when eluted with 150 lL of
PBS, but seven, eight and 14 HIV-reactive samples
were wrongly diagnosed as HIV-negative after
elution with 200, 250 and 500 lL of PBS, respec-
tively (Table 1). Therefore, 150 lL of PBS was
used to elute samples for the remainder of this
study.
Paired serum and DBS samples from 225
known HIV-reactive individuals, with high and
low OD values, and 50 known HIV non-reactive
individuals were then used for standardisation.
There was 100% correlation between the results
obtained using DBS and serum samples.
The Murex Ag ⁄Ab Combination assay was
then performed according to the manufacturer’s
instructions with 12 617 DBS eluates [11]. A
subset of 585 samples belonging to individuals
who were considered to be at relatively high risk
for HIV infection, based on their responses to a
questionnaire concerning sexual behaviour, but
which were negative for both antibody and
antigen, were tested for HIV-1 DNA by PCR
(Amplicor HIV 1 DNA v.1.5; Roche Molecular
Diagnostics, Branchburg, NJ, USA) in pools of ten
samples. In addition, a random sample of 10% of
all samples negative for HIV antibody, antigen or
nucleic acid (n = 1238) underwent quality assur-
ance testing; i.e., the Murex HIV Ag ⁄Ab Combi-
nation assay was used to test individual
specimens, and the Amplicor PCR was used to
test ten-sample pools. Pooling of 96–100 samples
for PCR has been reported not to lead to loss of
sensitivity in the detection of HIV [14,15]. PCR
could not be performed on all of the negative
samples because of lack of funds, and hence some
testing bias could not be avoided.
Of the 12 617 samples examined, 242 were
HIV-positive according to the Murex HIV
Ag ⁄Ab Combination assay [11]. Of these, 238
were positive for HIV antibodies according to
the Murex HIV Ab assay, and two were positive
for HIV p24 antigen alone according to the Vidas
HIV p24 antigen assay (bioMe´rieux, Marcy l’Eto-
ile, France). The remaining two reactive samples
were negative for HIV-1 DNA. Of the 585
negative samples from high-risk individuals,
one sample was positive for HIV-1 DNA accord-
ing to PCR. Of the 238 HIV antibody-positive
samples, 221 (92.86%) were positive for HIV-1,
14 (5.9%) were positive for HIV-2, and three
(1.3%) were positive for both HIV-1 and HIV-2
(TRI-DOT assay; J Mitra & Co., New Delhi,
India). All of the test runs were valid, as all of
the negative control OD values were <0.15, thus
meeting the assay criteria. Reproducible OD
values were observed with the 1238 HIV-nega-
tive samples that were re-run as part of the
quality assurance testing. The individual giving
the single sample that was negative according to
the Murex assay and positive according to PCR
was probably in the early phase of HIV infection,
in which both the antigen and the antibodies are
below the detectable level.
In conclusion, the Murex Ag ⁄Ab Combination
assay was highly sensitive and speciﬁc when used
to analyse DBSs, and detects p24 antigen in
addition to HIV-1 and HIV-2 antibodies. This
suggests that the test could be used in conjunction
with DBSs for large-scale ﬁeld studies of HIV,
particularly in India, which has the second largest
population of HIV-infected individuals (c. 5 mil-
lion) after Africa (http://www.nacoonline.org/
fnlapil06rprt.pdf). The study results are of partic-
ular relevance to developing countries, in which
Table 1. OD readings obtained using the Murex Ag ⁄Ab
Combination assay with 48 known human immunodeﬁ-
ciency virus (HIV)-reactive samples following elution from

















High OD 42 31 28 21
Low OD 2 7 9 13
Negative 0 6 7 10
HIV-2
(n = 2)
High OD 1 0 0 0
Low OD 1 2 2 0
Negative 0 0 0 2
HIV-1 + 2
(n = 1)
High OD 1 0 0 0
Low OD 0 1 1 0




High OD 0 0 0 0
Low OD 1 0 0 0
Negative 0 1 1 1
Total
(n = 48)
High OD 44 31 28 21
Low OD 4 10 12 13











p value <0.0001 <0.0001 <0.0001 <0.0001
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there is a need to carry out large population-based
studies of HIV.
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